Bengaluru biopharma company that makes generic APIs and complex formulations, including GLP-1 peptides. Holds US DMFs for liraglutide, semaglutide and tirzepatide.
- Model
- Manufacturer
- Manufacturer?
- Yes
Micafungin is a cyclic lipopeptide echinocandin antifungal (Mycamine).
5 listed companies hold an active US Type II Drug Master File for Micafungin API, based in India (3), Netherlands (1), China (1). 3 have a regulator record of GMP manufacturing.
Ordered by score. Scores follow the published rules and are not affected by paid placement. Updated 2026-11-13.
Source: FDA Drug Master File list. Holding a DMF is a regulatory filing, not an FDA approval.
Bengaluru biopharma company that makes generic APIs and complex formulations, including GLP-1 peptides. Holds US DMFs for liraglutide, semaglutide and tirzepatide.
Hyderabad-based MSN Group entity holding US DMFs for 11 peptide APIs, including semaglutide and tirzepatide. MSN runs 27 plants in India, the USA and Indonesia.
Dutch holding entity of TAPI, Teva's API and CDMO business, with peptide development and GMP production across a global plant network. Holds US DMFs for 9 peptide APIs.
Main operating subsidiary of Hong Kong-listed Hansoh Pharma, founded 1995; holds US DMFs for degarelix and icatibant.
Privately held Hyderabad generics and API group with 36+ plants; US DMFs for semaglutide and vasopressin.
Companies holding active US DMFs for Micafungin include Biocon Ltd, MSN Life Sciences Private Ltd (MSN Group), TAPI NL B.V. (TAPI), Jiangsu Hansoh Pharmaceutical Group Co., Ltd and Hetero Drugs Ltd. Other manufacturers may supply it without a US DMF.
Among listed DMF holders: India (3), Netherlands (1), China (1).
No. FDA reviews a DMF when a drug application references it and does not approve DMFs on their own.